Bejan-Angoulvant T - Search Results

1

Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.

Gueyffier F, Subtil F, Bejan-Angoulvant T, Zerbib Y, Baguet JP, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Maucort-Boulch D, Erpeldinger S; IDEAL Trial Group. Gueyffier F, et al. J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17. J Hum Hypertens. 2015. PMID: 24739801 Clinical Trial.

2

Do we need to assess the effect of treatment withdrawal? The paradigm of life-long prevention.

Gueyffier F, Bejan-Angoulvant T. Gueyffier F, et al. Stroke. 2007 Oct;38(10):2629-30. doi: 10.1161/STROKEAHA.107.492264. Epub 2007 Aug 30. Stroke. 2007. PMID: 17761906 No abstract available.

3

[Critical of the additive model of the randomized controlled trial].

Boussageon R, Gueyffier F, Bejan-Angoulvant T, Felden-Dominiak G. Boussageon R, et al. Therapie. 2008 Jan-Feb;63(1):29-35. doi: 10.2515/therapie:2008015. Epub 2008 Apr 4. Therapie. 2008. PMID: 18387273 Review. French.

4

Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials.

Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, Schron EB, Lindholm LH, Fagard R, Staessen JA, Gueyffier F. Bejan-Angoulvant T, et al. J Hypertens. 2010 Jul;28(7):1366-72. doi: 10.1097/HJH.0b013e328339f9c5. J Hypertens. 2010. PMID: 20574244

5

Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets.

Gueyffier F, Perez MI, Wright JM, Marchant I, Musini VM, Bejan-Angoulvant T. Gueyffier F, et al. J Hypertens. 2011 Jan;29(1):171-3; author reply 173-5. doi: 10.1097/HJH.0b013e3283409240. J Hypertens. 2011. PMID: 21160363 No abstract available.

6

[The problem of blood pressure targets].

Boussageon R, Bejan-Angoulvant T, Gueyffier F. Boussageon R, et al. Rev Med Suisse. 2011 Apr 20;7(291):873; author reply 873. Rev Med Suisse. 2011. PMID: 21598729 French. No abstract available.

7

[Modeling of systolic blood pressure reaction to antihypertensive agents in people with hypertension].

Wu Y, Li YS, Bejan-Angoulvant T, Gueyffier F. Wu Y, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Apr;39(4):309-14. doi: 10.3760/cma.j.issn.0253-3758.2011.04.006. Zhonghua Xin Xue Guan Bing Za Zhi. 2011. PMID: 21624305 Chinese.

8

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Boussageon R, et al. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. BMJ. 2011. PMID: 21791495 Free PMC article. Review.

9

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.

Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C. Boussageon R, et al. PLoS Med. 2012;9(4):e1001204. doi: 10.1371/journal.pmed.1001204. Epub 2012 Apr 10. PLoS Med. 2012. PMID: 22509138 Free PMC article.

10

The IDEAL study : towards personalized drug treatment of hypertension.

Bejan-Angoulvant T, Baguet JP, Erpeldinger S, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Gueyffier F; IDEAL Study Group. Bejan-Angoulvant T, et al. Therapie. 2012 May-Jun;67(3):195-204. doi: 10.2515/therapie/2012031. Epub 2012 Aug 9. Therapie. 2012. PMID: 22874485 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters